Celltrion

Temasek's Ion Investments to divest stake in South Korean pharma for $1.35b block deal

SINGAPORE (Mar 7): Ion Investments, which is controlled by Temasek Holdings of Singapore, is selling part of its stake in South Korean pharmaceutical company Celltrion and distributor Celltrion Healthcare, IFR reported on Tuesday, citing a term sheet.
×